Its role Owner
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics Inc., it pioneered the use of recombinant DNA technology to develop biologic medicines.
The company discovers, develops, manufactures, and markets human therapeutics for serious illnesses, including cancer, cardiovascular disease, osteoporosis, inflammatory conditions, and rare diseases. Key products include Prolia and Xgeva (denosumab) for bone diseases, Enbrel (etanercept) for autoimmune disorders, Repatha (evolocumab) for hyperlipidemia, Otezla (apremilast) for psoriasis, Tepezza (teprotumumab) for Graves' ophthalmopathy, Kyprolis (carfilzomib) for multiple myeloma, and others such as Aranesp, Neulasta, and Nplate.
Amgen operates in approximately 100 countries with manufacturing facilities in the US, Puerto Rico, Ireland, the Netherlands, and Singapore. It is publicly traded on Nasdaq (AMGN) and ranks among the largest biomedical companies by revenue.
chemXplore tracks 4 projects involving Amgen, of which 3 are active.
Besides these 3, the record holds 1 completed project.
Closest to start-up first.
The 1 that is completed, on hold or cancelled are in the record. See all 4 in chemXplore →
Real‑world analysis of 544,103 adults with ASCVD followed up to four years; comparative non‑statin outcomes evidence to inform treatment choices and LDL‑C goal attainment.
Total revenues rose 8% to $10.4B; GAAP EPS $7.08; 17 products annualizing >$1B; full-year revenue guidance $38.9–$39.7B with up to $3.0B share repurchases.
Phase 3 OASIZ‑301: dazodalibep (CD40L antagonist) showed greater ESSDAI reduction at Week 48 vs placebo, improved patient‑reported dryness, and similar safety across groups.
Phase 3 DeLLphi‑305: IMDELLTRA with durvalumab raised median OS to 21.1 vs 12.7 months, tripled PFS, and produced ~80% one‑year survival versus 53%.
Phase 3 CROSSING found TEZSPIRE produced sustained histologic remission, reduced dysphagia scores and achieved endoscopic remission through week 52 in adolescents and adults with eosinophilic esophagitis.
Phase 3 trial showed rapid, sustained reduction in systemic disease activity in moderate-to-severe Sjögren's disease with manageable safety signals.
Tarlatamab (IMDELLTRA) plus durvalumab showed statistically significant OS, PFS and ORR benefits versus durvalumab alone in Phase 3 DeLLphi‑305 for first‑line maintenance ES‑SCLC.
Pre‑specified VESALIUS‑CV analysis shows evolocumab plus background therapy lowers deaths and major CV events in high‑risk adults without prior MI/stroke.
active all projects
